Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185069 | 0.93 | CHRM2 (0.60) | CHRM2CHRM3 | |
| SCHEMBL3183768 | 0.91 | CHRM2 (0.63) | CHRM2CHRM3 | |
| SCHEMBL3185671 | 0.89 | CHRM2 (0.62) | CHRM2CHRM3 | |
| SCHEMBL267952 | 0.89 | CHRM2 (0.62) | CHRM2CHRM3 | |
| SCHEMBL3194575 | 0.88 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL267576 | 0.88 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL265208 | 0.88 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL266994 | 0.88 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL265513 | 0.88 | CHRM2 (0.60) | CHRM2CHRM3 | |
| SCHEMBL264835 | 0.88 | CHRM2 (0.60) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659403-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-[methyl(3-(2-[(thiophen-2-ylmethyl)amino]ethylcarbamoyl)benzoyl)amino]ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205784-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.